Wegovy vs Zepbound: Which GLP-1 Medication Wins for Weight Loss?

*This article is for informational purposes only. It is not medical advice. Speak with a licensed healthcare provider before starting any new medication or treatment program.*

---

The two most-discussed brand-name GLP-1 medications for weight loss are Wegovy and Zepbound. Both are once-weekly injections. Both produce meaningful, clinically significant weight loss. And both carry a list price above $1,000 per month without insurance.

But they are not the same drug. Wegovy contains semaglutide, a GLP-1 receptor agonist. Zepbound contains tirzepatide, a dual GLP-1 and GIP receptor agonist. That mechanistic difference translates into real differences in average weight loss outcomes, side effect rates, and out-of-pocket cost.

This guide covers the clinical trial data, side effect profiles, 2026 pricing, and the path to compounded alternatives for patients who cannot access either brand.

*Wegovy and Zepbound are brand-name FDA-approved medications. Compounded semaglutide and compounded tirzepatide are not FDA-approved.*

---

What Are Wegovy and Zepbound?

Wegovy (Semaglutide 2.4 mg)

Wegovy is a brand-name prescription medication manufactured by Novo Nordisk. The FDA approved it in June 2021 for chronic weight management in adults with:

• Obesity (BMI 30 or higher)
• Overweight (BMI 27 or higher) with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol

The active ingredient in Wegovy is semaglutide at a dose of 2.4 mg per week. Semaglutide works by mimicking GLP-1 (glucagon-like peptide-1), a naturally occurring gut hormone that signals fullness to the brain, slows gastric emptying, and helps regulate blood sugar. This is a single-receptor mechanism.

Patients inject Wegovy once weekly into the abdomen, thigh, or upper arm. The starting dose is 0.25 mg, increasing gradually over 16 to 20 weeks to reach the 2.4 mg maintenance dose.

Brand names for semaglutide: Wegovy (weight management) and Ozempic (type 2 diabetes).

Zepbound (Tirzepatide)

Zepbound is a brand-name prescription medication manufactured by Eli Lilly. The FDA approved it in November 2023 for chronic weight management, using the same BMI criteria as Wegovy.

The active ingredient is tirzepatide, a "twincretin" that activates two gut hormone receptors simultaneously: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP plays a role in energy storage and fat metabolism alongside GLP-1's appetite-suppressing effects. Activating both pathways together appears to produce greater weight loss than either pathway alone.

Zepbound doses range from 2.5 mg to 15 mg, injected once weekly. Patients start at 2.5 mg and increase toward a target maintenance dose of 10 mg or 15 mg.

Brand names for tirzepatide: Zepbound (weight management) and Mounjaro (type 2 diabetes). Same molecule, different FDA indication.

For more on how these two drug classes compare as generic ingredients, see [semaglutide vs tirzepatide](/resources/semaglutide-vs-tirzepatide-which-glp1-is-right-for-you).

---

Efficacy: Which One Produces More Weight Loss?

This is the central clinical question. The short answer: Zepbound (tirzepatide) produces greater average weight loss in clinical trials, including a 2025 direct head-to-head comparison.

Wegovy Data: STEP 1 Trial

The landmark Wegovy trial is STEP 1, a Phase 3 randomized controlled trial of 1,961 adults. Participants received semaglutide 2.4 mg weekly alongside lifestyle counseling for 68 weeks.

Average result: 14.9% body weight reduction, compared to 2.4% in the placebo group. For a person starting at 230 pounds, that is approximately 34 pounds of weight loss ([PMID: 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)).

Zepbound Data: SURMOUNT-1 Trial

The landmark Zepbound trial is SURMOUNT-1, which enrolled 2,539 adults with obesity or overweight. Participants received tirzepatide at 5 mg, 10 mg, or 15 mg once weekly for 72 weeks.

Results by dose:

• 15 mg: 22.5% average weight reduction
• 10 mg: 21.4% average weight reduction
• 5 mg: 16% average weight reduction

All doses significantly outperformed placebo ([PMID: 35658024](https://pubmed.ncbi.nlm.nih.gov/35658024/)).

Head-to-Head: SURMOUNT-5

The most definitive data point for this comparison comes from SURMOUNT-5, a 2025 head-to-head randomized trial that directly compared tirzepatide (10 mg and 15 mg) against semaglutide 2.4 mg in adults with obesity.

Results: Tirzepatide users lost an average of 20.2% of body weight. Semaglutide users lost 13.7%. The difference was statistically significant, favoring tirzepatide ([PMID: 39764728](https://pubmed.ncbi.nlm.nih.gov/39764728/)).

What This Means in Practice

On a population level, tirzepatide's dual-receptor mechanism produces meaningfully greater average weight loss than semaglutide. The SURMOUNT-5 gap (20.2% vs 13.7%) is clinically significant. At the same time, trial averages hide wide individual variation. Some people respond strongly to semaglutide. Some do not tolerate tirzepatide. Provider guidance, personal health history, and prior medication experience all matter as much as average trial results.

---

Side Effects: Wegovy vs Zepbound Compared

Both medications share a similar side effect profile because they act on overlapping pathways. Gastrointestinal (GI) symptoms are the most common, particularly in the first weeks of treatment as the dose increases.

GI Side Effects: Side-by-Side Comparison

In the SURMOUNT-5 head-to-head, fewer tirzepatide users discontinued treatment due to GI side effects (6.6%) compared to semaglutide users (8.0%). However, Wegovy has been on the market since 2021, so its tolerability profile has more extensive real-world documentation.

GI side effects are generally temporary and dose-dependent. Slow dose escalation significantly reduces their severity for most patients.

Serious Side Effects (Both Medications)

Both Wegovy and Zepbound carry a boxed warning for thyroid C-cell tumors, based on animal studies. Human risk is not established, but both medications are contraindicated for people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

Additional serious side effects relevant to both:

• Pancreatitis (rare): Seek immediate medical attention for severe, persistent abdominal pain
• Gallbladder problems: Gallstones occur more frequently with rapid weight loss
• Kidney injury: Usually secondary to dehydration from severe GI side effects
• Vision changes: Report any new or worsening visual symptoms to your provider
• Increased heart rate: Both medications can mildly increase resting heart rate

These risks apply to both medications. Your prescribing provider will evaluate your history for relevant contraindications before starting either drug.

---

Cost: Wegovy vs Zepbound Without Insurance

Out-of-pocket cost is one of the most practically significant differences between these two medications in 2026.

Brand-Name List Prices (2026)

Zepbound carries roughly a $290/month lower list price than Wegovy in 2026. Over 12 months without insurance, that difference exceeds $3,400.

Manufacturer Savings Cards

Both companies offer savings programs for eligible commercially insured patients:

• Lilly Savings Card (Zepbound): As low as $25/month for eligible insured patients
• Novo Nordisk Patient Assistance (Wegovy): Variable copay support; NovoCare program available for qualifying uninsured patients

These programs do not cover Medicare or Medicaid patients. Program terms can change.

Insurance Coverage Requirements

Insurance coverage for both Wegovy and Zepbound is similar in structure. Most plans that cover either medication require:

• BMI 30+ (obesity) or BMI 27+ with a documented comorbidity
• Prior authorization
• Documentation of prior lifestyle interventions
• Prescriber attestation of clinical appropriateness

Coverage is inconsistent across commercial plans, and many patients who qualify clinically face denials or lengthy prior authorization delays.

Compounded Alternatives: Cost Comparison

Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not the same products as Wegovy or Zepbound. With that distinction clearly understood, compounded formulations are available through licensed 503A compounding pharmacies at substantially lower cost.

For patients who cannot access manufacturer savings cards or who are denied insurance coverage, the cost difference between brand and compounded is significant. See [how much compounded semaglutide costs](/resources/compounded-semaglutide-cost-2026) for current program details.

---

Availability and Access

Wegovy Availability in 2026

Wegovy experienced a significant supply shortage beginning in late 2022, driven by demand outpacing Novo Nordisk's manufacturing capacity. That shortage prompted many patients to seek alternatives, including compounded semaglutide. As of 2026, Wegovy supply is substantially more stable. See the full [semaglutide shortage history](/resources/semaglutide-shortage-2026) for context on how access has evolved.

Zepbound Availability in 2026

Zepbound has also faced intermittent supply disruptions. Current availability varies by dose and pharmacy. For the most current [tirzepatide shortage 2026](/resources/tirzepatide-shortage-2026) information, check directly with your pharmacy or prescriber.

Telehealth Access

Both Wegovy and Zepbound are accessible through licensed telehealth platforms that can connect patients with prescribers online. For patients who cannot access or afford brand-name options, telehealth providers including Prescriva also facilitate evaluations for compounded semaglutide and compounded tirzepatide where clinically appropriate.

---

Wegovy vs Zepbound: Which Should You Choose?

The right choice depends on your health history, metabolic profile, cost considerations, and your provider's clinical judgment. Neither medication is universally superior. Here is a practical framework.

Wegovy (semaglutide) may be the better fit if:

• You have established cardiovascular disease: The SELECT trial demonstrated semaglutide reduced major cardiovascular events by 20% in overweight and obese patients with cardiovascular disease
• You prefer the longer market track record (Wegovy approved 2021 vs Zepbound 2023)
• You previously tolerated lower-dose semaglutide through Ozempic and want to continue the same active drug at a higher dose
• Your provider has stronger clinical experience with semaglutide

Zepbound (tirzepatide) may be the better fit if:

• Maximum weight loss is the primary goal and the SURMOUNT-5 advantage is meaningful to you
• You have insulin resistance, prediabetes, or type 2 diabetes (the dual GIP/GLP-1 mechanism may offer additional metabolic benefits)
• You have not responded adequately to semaglutide in the past
• Cost is a significant factor and you do not qualify for Wegovy savings programs (Zepbound has a lower list price)

Neither medication is appropriate if:

• You have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome
• You have a history of severe pancreatitis
• You are pregnant or planning to become pregnant
• You have specific other contraindications your provider will identify

If brand-name access is the barrier, both [compounded semaglutide](/resources/compounded-semaglutide-what-it-is) and [compounded tirzepatide](/resources/compounded-tirzepatide-guide) are available through licensed 503A compounding pharmacies at significantly lower monthly cost.

---

The Compounded Alternative to Both

For patients who are denied insurance coverage, cannot afford brand-name list prices, or face ongoing supply issues, compounded formulations represent an important access pathway.

Licensed 503A compounding pharmacies prepare individualized semaglutide and tirzepatide formulations using pharmaceutical-grade active drug substances. These preparations require a valid prescription and are patient-specific. They are not FDA-approved, they are not manufactured by Novo Nordisk or Eli Lilly, and they are not equivalent to Wegovy or Zepbound. Patients and providers must understand this distinction clearly.

Under 21 U.S.C. § 503A, a licensed 503A compounding pharmacy may prepare patient-specific compounded medications when a prescriber determines this is clinically appropriate for an individual patient. Prescriva facilitates evaluations and, where appropriate, access to compounded semaglutide starting from $169/mo and compounded tirzepatide starting from $259/mo (52-week plans), including clinician consultation and delivery.

---

Frequently Asked Questions

Is Zepbound stronger than Wegovy?

In clinical trials, Zepbound (tirzepatide) produced greater average weight loss than Wegovy (semaglutide). The SURMOUNT-5 head-to-head trial showed 20.2% versus 13.7% average weight loss, favoring tirzepatide. Individual results vary based on health history and dose response.

Can I switch from Wegovy to Zepbound?

Switching between GLP-1 medications is possible and clinically appropriate in some situations, for example when you are not achieving adequate results on semaglutide or when tirzepatide is better suited to your metabolic profile. A provider manages the transition, including appropriate dosing adjustments.

Which has fewer side effects: Wegovy or Zepbound?

Both medications cause similar GI side effects. In SURMOUNT-5, tirzepatide had a slightly lower nausea rate (31% vs 44%) and fewer discontinuations due to GI side effects. Wegovy has more extensive real-world tolerability data given its longer market presence. Individual tolerance varies.

Is compounded semaglutide the same as Wegovy?

No. Compounded semaglutide is not FDA-approved and is not the same product as Wegovy. Wegovy is an FDA-approved medication manufactured by Novo Nordisk under specific quality standards. Compounded semaglutide is prepared by a licensed 503A compounding pharmacy per individual prescription. Patients should discuss this distinction with their prescribing provider before starting.

Which is cheaper: Wegovy or Zepbound?

Zepbound has a lower list price (~$1,060/month vs ~$1,350/month for Wegovy in 2026). Both become substantially more affordable through compounded alternatives: compounded semaglutide from $169/mo and compounded tirzepatide from $259/mo on 52-week plans.

---

Conclusion

Wegovy and Zepbound are both effective FDA-approved GLP-1 medications for chronic weight management. The clinical evidence consistently shows that Zepbound (tirzepatide) produces greater average weight loss, a finding confirmed in the 2025 SURMOUNT-5 head-to-head trial. Wegovy (semaglutide) carries a longer track record and strong cardiovascular data in patients with established heart disease.

For most patients, the largest practical barrier is not which medication is marginally superior. It is cost and access. At $1,060 to $1,350 per month without insurance, both remain out of reach for many people. Compounded semaglutide and compounded tirzepatide provide access to these pharmaceutical ingredients through licensed 503A pharmacies at substantially lower monthly cost, with the important caveat that compounded versions are not FDA-approved.

Ready to explore whether you qualify? Prescriva offers a personalized clinical assessment to determine the right approach for your weight management goals.

[Start your personalized assessment at Prescriva](https://prescriva.com/start)

---

*This article is for informational purposes only and does not constitute medical advice. Wegovy and Zepbound are brand-name FDA-approved medications. Compounded semaglutide and compounded tirzepatide are not FDA-approved. Consult your licensed healthcare provider before starting, stopping, or changing any medication.*

---

References

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PMID: 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PMID: 35658024](https://pubmed.ncbi.nlm.nih.gov/35658024/)
3. Jastreboff AM et al. Tirzepatide vs. Semaglutide for Obesity (SURMOUNT-5). N Engl J Med. 2025. [PMID: 39764728](https://pubmed.ncbi.nlm.nih.gov/39764728/)
4. Wegovy (semaglutide injection) Prescribing Information. Novo Nordisk Inc. 2021.
5. Zepbound (tirzepatide injection) Prescribing Information. Eli Lilly and Company. 2023.
6. 21 U.S.C. § 503A. Federal Food, Drug, and Cosmetic Act: Pharmacy Compounding.